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LRRK2 is one of the most important genetic contributors to Parkinson’s disease (PD). Point mutations in
this gene cause an autosomal dominant form of PD, but to date no cellular phenotype has been consis-
tently linked with mutations in each of the functional domains (ROC, COR and Kinase) of the protein
product of this gene. In this study, primary ﬁbroblasts from individuals carrying pathogenic mutations
in the three central domains of LRRK2 were assessed for alterations in the autophagy/lysosomal pathway
using a combination of biochemical and cellular approaches. Mutations in all three domains resulted in
alterations in markers for autophagy/lysosomal function compared to wild type cells. These data high-
light the autophagy and lysosomal pathways as read outs for pathogenic LRRK2 function and as a marker
for disease, and provide insight into the mechanisms linking LRRK2 function and mutations.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. 1. Introduction
Leucine Rich Repeat Kinase 2 (LRRK2) is a multidomain protein
of unclear function containing two enzymatic domains, a GTPase
(Ras of Complex Proteins, ROC) and a kinase, connected by a C-ter-
minal of ROC (COR) domain and ﬂanked by protein/protein interac-
tion domains [1]. LRRK2 has been implicated in a number of
cellular processes, including the control of neurite branching, syn-
aptic vesicle recycling, macroautophagy (hereafter referred to asautophagy), protein synthesis through the mTOR pathway and
mitochondrial function [2].
The central role of LRRK2 in Parkinson’s disease (PD) has been
highlighted by the discovery of autosomal dominant mutations
in LRRK2 causing familial PD and the subsequent identiﬁcation of
the LRRK2 locus as a risk factor for sporadic disease [3,4]. A key
question regarding the role of autosomal dominant coding change
mutations in PD is what the cellular consequences of these muta-
tions are, and how they lead to disease [2]. All known highly pene-
trant missense mutations (N1437H, R1441C, R1441G, Y1699C,
I2012T, G2019S, I2020T) are located in the enzymatic core of
LRRK2 – the ROC/COR/kinase triad [4], leading to a number of stud-
ies examining the impact of mutations on the enzymatic activities
of this protein. The G2019S mutation, the most common disease
linked variant in LRRK2 in Europeans, has been consistently associ-
ated with increased kinase activity, and mutations in the ROC and
COR domains display reduced GTPase activity [5–9]. However, no
single biochemical phenotype has been linked to mutations in all
three of these domains. The only reported cellular phenotype that
Fig. 1. LC3-II/LC3-I ratio after starvation is altered in ﬁbroblasts carrying LRRK2
mutations. (A) Immunoblot analysis reveals that LRRK2 is expressed at equivalent
levels in the ﬁbroblast cells used in this study. (B) Under normal growing conditions
(+) no differences between genotypes are observed in the ratio of LC3-I to LC3-II,
with LC3-I the most abundant form. After starvation from serum and aminoacids (–
), LC3-II increases and LC3-I decreases in wild type ﬁbroblasts thus leading, as
expected, to an overall increase in the LC3-II/LC3-I ratio, shown in (C). For all the
mutant ﬁbroblasts after starvation, the increase in LC3-II and the concomitant
decrease in LC3-I is less evident thus leading to a signiﬁcantly smaller increase in
the LC3-II/LC3-I ratio when compared with starved wild type cells (one-way
ANOVA, Dunnett’s test, * p < 0.05). The gel is representative of 6 independent
experiments, with data pooled to generate the graph in which means and standard
deviations are shown. 3 different wild type lines, 2 different R1441G, 2 different
G2019S and 1 Y1699C mutant lines have been used.
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which is dependent upon kinase activity [10–12].
A major gap in our understanding of LRRK2 pathobiology is,
therefore, a biological phenotype for LRRK2 that correlates with
disease genotype. The identiﬁcation of a phenotype common to
all pathogenic mutations would provide a target for drug testing
in a manner analogous to the use of Ab42 levels in Alzheimer ther-
apies [13,14]. Moreover, it would indicate a speciﬁc pathway to be
studied to ﬁnd markers for early diagnosis of disease, an urgent un-
met need for PD [15].
A number of studies have highlighted a putative role for LRRK2
in the regulation of the autophagy/lysosomal pathway. Several
groups have reported an impact of the common G2019S mutation
(located in the kinase domain of LRRK2) on either basal or induced
autophagy [16–21]. Mutations in the ROC domain of LRRK2 have
also been reported to alter autophagy in human and yeast models
for LRRK2 [17,22]. With regard to the physiological function of
LRRK2, both knockout, knockdown and chemical inhibition of
LRRK2 have been reported to alter autophagy [17,23,24]. Based
on these reports, human ﬁbroblasts carrying mutations across
the enzymatic core of LRRK2 were compared to wild type cells in
order to test whether there is a consistent impact of these muta-
tions upon the autophagy/lysosomal pathway.
2. Materials and methods
2.1. Antibodies
Antibodies used were as follows: rabbit LC3 antibody (NB100-
2220, Novus Biologicals); LRRK2 antibodies (3514-1, Epitomics);
total S6 antibody (2317, Cell Signaling); phospho Ser235/236 S6
antibody (2211S, Cell Signaling); total P70S6K antibody (sc-8418,
Santa Cruz); phospho Thr389 P70S6K (sc-11759, Santa Cruz); total
4EBP1 (81149, Santa Cruz); phospho Ser65 4EBP1 (9451S, Cell Sig-
naling); mouse p62 antibody (610833, BD Transduction Labs); rab-
bit p62 antibody (BML-PW9860-0025, Enzo Life Sciences); mouse
WIPI2 antibody (kindly supplied by Dr. S.Tooze); mouse LAMP1
(H4A3, Abcam) andmouse b-actin antibody (A1978, Sigma Aldrich).
2.2. Cell culture and Western blotting
Fibroblasts were grown in DMEM containing 10% FCS. Fibro-
blasts were isolated from genetically deﬁned individuals following
local ethical approval and full informed consent (see Ref. [25] for
details). mTOR inhibition was achieved by overnight (16 h) serum
deprivation followed by substitution of the medium with Earle’s
balanced salts solution for 2 h. Re-activation of the mTOR pathway
was obtained by MEM non-essential amino acid supplement added
for 30 min to the ﬁbroblast culture after starvation. Cells were col-
lected in DPBS; the cell pellet was washed once and then lysed in a
buffer containing: 0.5% Triton X-100, 2 mM EDTA, 150 mM NaCl,
0.5% sodium deoxycholate, 0.1% SDS, protease inhibitors (cOm-
plete, Roche) and phosphatase inhibitors (Halt, Pierce) in 50 mM
TRIS–HCl pH 7.5. Cell lysates were frozen immediately upon collec-
tion. Following thawing, lysates were clariﬁed by centrifugation at
10000g for 5 min at 4 C and the protein concentration was as-
sessed by BCA assay (BCA Protein Assay Kit, Pierce). 10 lg aliquots
were prepared, denatured in NuPAGE sample buffer (Invitrogen)
for 10 min at 70 C and analysed by immunoblot as previously de-
scribed [24]. Statistical analyses were performed by the use of the
Prism software (GraphPad) as described in the text.
2.3. Immunocytochemistry
Cells were plated and analysed by ICC as previously described
[24]. For the quantiﬁcation experiments, images were acquiredwith a Leica CTR 6000 ﬂuorescence microscope, and processed by
the LAS AF Lite software. Cell counts for WIPI2 puncta or p62
immunoreactivity were performed on the acquired images manu-
ally by a blinded operator using the cell counter plugin tool in the
ImageJ software package. Graphs and statistical analyses were per-
formed using Prism software.3. Results
The impact of mutations in the three central domains of LRRK2
upon autophagy and lysosomal function were assessed in patient
derived ﬁbroblasts harboring LRRK2 mutations – the R1441G
mutation in the ROC/GTPase domain, the Y1699C mutation in the
COR domain and the G2019S mutation in the kinase domain –
and age/sex matches control cells [25]. Levels of LRRK2 protein
were comparable in wild type and mutation carrying cells (Fig. 1A).
To investigate autophagy pathways in the presence and absence
of mutations in LRRK2, the autophagic marker LC3 was examined
under normal growth conditions and following starvation from
serum and amino acids (Fig. 1B and C). No differences were ob-
served in LC3 processing (as measured by conversion of LC3-I,
the cytosolic form of LC3, into the vesicle associated LC3-II form
of the protein) between genotypes under normal growth condi-
tions. Under starvation conditions, a signiﬁcant difference was ob-
served between wild type and mutant cells in the ratio between
LC3-I and LC3-II, suggesting that mutations in LRRK2 disrupt the
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niﬁcant alteration in the ratio of LC3-II to b-actin was observed be-
tween genotypes (data not shown), suggesting that the impact of
LRRK2 mutations upon starvation-induced autophagy is more
complex than a straightforward increase in bulk autophagy. This
was further emphasized by the absence of detectable changes in
p62 levels when analyzed by immunoblot after starvation across
wild type and mutant ﬁbroblasts or in levels of LAMP1, a marker
for the lysosomes (Supplemental Fig. 1). To investigate the auto-
phagic response of LRRK2 mutation carrying cells using an alterna-
tive technique, autophagic vesicle formation was assessed by ICC
under normal growing and starvation conditions. Using the vesic-
ular marker WIPI2 and p62, a signiﬁcant difference in p62 positive
cells and in WIPI2 positive puncta per cell were observed for the
R1441G and Y1699C mutations compared to wild type cells under
starvation conditions (see Fig. 2). No differences were observed be-
tween wild type and G2019S mutation cells. To establish whether
these alterations were accompanied by changes in mTORC1 signal-
ing, a key regulator of autophagy and translational repression, the
phosphorylation states of p70S6K, S6 and 4EBP1 were evaluated
(Fig. 3A and B). No differences were observed between genotypes
under either normal growing conditions or following starvation.Fig. 2. Immunocytochemistry reveals alterations in the amount of p62 positive cells andW
cells. The percentage of p62 positive cells (A) and the amount of WIPI2 puncta per cells (B
p62 positive cells and the amount of WIPI2 puncta per cells always increase after starva
Y1699C mutation carriers are signiﬁcantly smaller than those observed for the wild typ
Dunnett’s post hoc test using starved wild type as reference). WIPI2 puncta: an average o
starvation reaching a total number of counted cells as follows: 131, wild type control; 15
Y1699C starved; 73 R1441G control, 75 R1441G starved. P62 positive cells: for every
magniﬁcation. The total number of counted cells was as follows: 344, wild type control, 3
117 Y1699C starved; 355 R1441G control, 318 R1441G starved.4. Discussion
Mutations in LRRK2 cause an autosomal dominant form of PD
that is almost indistinguishable from the idiopathic form of the dis-
ease. Since 2004, a number of cellular processes have been linked
to the function of LRRK2, however no cellular phenotype has been
found to be altered in the same way by penetrant mutations in
each of the three central domains of LRRK2. This has left a major
gap in our understanding of the disease process deriving from
these mutations. The results from this study demonstrate that
three penetrant mutations in the ROC, COR and kinase domains
of LRRK2 result in an altered cellular response to starvation condi-
tions as reﬂected in altered pools of cytosolic and membrane asso-
ciated LC3. These data support a pathogenic mechanism consistent
with alterations in the autophagy-lysosomal pathway and in gen-
eral vesicle metabolism, with a possible mechanistic dichotomy
between mutations in the ROC-COR and kinase domains. Although
the exact mechanism(s) whereby LRRK2 impacts on LC3 processing
is unclear, these data echo, in a physiological cellular system, pre-
vious reports from overexpression model systems implicating
LRRK2 in the cellular process of autophagy and lysosomal degrada-
tion [16,17,19,21,22].IPI2 puncta in starved ﬁbroblasts carrying LRRK2 mutations compared to wild type
) have been assessed under basal and starved growing conditions. The percentage of
tion indicating an activation of autophagy. The increases observed for R1441G and
e cells. No differences were observed for the G2019S ﬁbroblasts (one-way ANOVA,
f 22 frames has been acquired at 60X magniﬁcation for each cell type in control and
2 wild type starved; 97 G2019S control, 117 G2019S starved; 36 Y1699C control, 78
sample 5 different frames from 2 independent slides have been acquired at 40x
14 wild type starved; 150 G2019S control, 198 G2019S starved; 170 Y1699C control,
Fig. 3. mTORC1 pathway phospho-state is not altered by mutations in LRRK2. Wild type and mutant ﬁbroblasts were assessed under normal growing conditions (+) and after
serum and aminoacids starvation (). Total levels of S6/p70S6K (A) and 4EBP1 (B) are identical for all the ﬁbroblasts analysed. No differences in phosphorylation are observed
between genotypes under either condition. 2 different wild type lines, 2 different R1441G, 2 different G2019S and one Y1699C mutant lines have been used.
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associated with the G2019S mutation at an endogenous level
[18,20]. In contrast to data in the current study, where a difference
between wild type and mutant cells is only observed under starva-
tion conditions, Bravo-San Pedro and colleagues observed an alter-
ation in basal autophagy in ﬁbroblasts from individuals carrying
the G2019S mutation. The most likely explanation for the different
results obtained in these two studies is that the culturing condi-
tions used to examine basal autophagy by Bravo-San Pedro et al.
are signiﬁcantly different to those used in the study presented
above. Sanchez-Danes and co-workers reported altered autophagy
in neurons differentiated from induced pluripotent stem cells that
had been derived from patients carrying the G2019S mutation,
suggesting that changes in the regulation of autophagy due to
mutations in LRRK2 are a feature of multiple cell types, including
cells impacted in Parkinson’s disease. In contrast to Bravo-San Ped-
ro (and similar to the data in this study), Sanchez-Danes et al. did
not observe an alteration in basal autophagy in the G2019S muta-
tion ﬁbroblasts from which the pluripotent cells they used in their
study were derived.
An important insight arising from the data reported above is the
absence of any alteration in the regulation of downstream transla-
tional targets of mTORC1 (either S6 or 4EBP1). This is in contrast to
a study in Drosophila melanogaster which suggested that LRRK2
regulated the phosphorylation of 4EBP1 [26], but is congruent with
recent studies that did not observe any interaction between LRRK2
and 4EBP1 either in vitro [27], or in mouse models or human brain
tissue [28].
Examining the catalytic domain triad of LRRK2, the ROC and
COR domains can be viewed as distinct from the kinase domain
from a functional, structural and evolutionary perspective [29].
The G2019S mutation, within the kinase domain, increases the ki-
nase activity of LRRK2; mutations in the GTPase (R1441G) and in
the COR (Y1699C) domains are linked to a decrease in the GTPase
activity. The data in this study demonstrate that mutations in the
ROC-COR domains alter the ability of the cell to respond to starva-
tion impairing the physiological increase in the concentration of
WIPI2 and p62 positive vesicles upon starvation. This was paired
by a dysregulation in the distribution between the membrane
bound and the cytosolic forms of LC3 thus suggesting that the
autophagy/lysosomal pathway may be potentially affected by the
R1441G and Y1699C mutations in LRRK2. The G2019S mutation
produced the same alteration in the metabolism of LC3 in the ab-
sence of concomitant changes in vesicle content during starvation,
suggesting that the precise route to dysfunction may be dependentupon which of LRRK2s enzymatic activities is impacted by muta-
tion. Given the complex relationship between the enzymatic activ-
ities of LRRK2, and the recent observation that the G2385R
polymorphism linked to disease risk in Asian populations acts to
decrease kinase activity [30], it is possible that disruption of enzy-
matic function per se is the key biochemical read out of LRRK2 dys-
function in PD – with distinct but convergent phenotypic
consequences. An important test of this will be examining the im-
pact of the G2385R polymorphism on autophagic response. The
precise mechanism whereby LRRK2 regulates autophagy remains
to be determined, however the data in this study and from studies
focusing on chemical inhibition of LRRK2 kinase activity [24] sug-
gest that this may be via a non-canonical autophagy pathway,
independent of mTORC1.
The observation that alterations in the autophagic lysosomal
pathway in response to starvation are common cellular feature of
LRRK2 mutations is important for several reasons. First, this reiter-
ates the importance of the autophagy/lysosomal pathway to neu-
rodegeneration, and in particular a role of this pathway in PD
[31,32]. The links between vesicle metabolism, lysosomes, autoph-
agy and protein misfolding diseases provide a plausible connection
between the cellular phenotype observed in this study, and the
pathogenesis and pathology of LRRK2 PD. Secondly, and indepen-
dent of the actual role in the pathological pathways leading to dis-
ease in LRRK2 cases, this cellular phenotype provides a read out for
LRRK2 dysfunction. This may be amenable to screening of com-
pounds directed against the pathogenic impact of LRRK2 muta-
tions, thereby providing a valuable tool in the urgent search for
modiﬁers of PD disease progression and early markers of disease.
This study also re-emphasizes the importance of studying a range
of mutations in LRRK2, rather than focusing on the most common
G2019S mutation. Finally, in the context of the role that LRRK2
plays in human disease, it is noteworthy that LRRK2 has been
implicated in a number of human disorders, including Crohn’s dis-
ease, Cancer and Leprosy in addition to PD [33]. The autophagy/
lysosomal pathway has been linked to all of these disorders, and
the observation that LRRK2 is intimately involved in this cellular
process may be relevant to its role numerous human conditions,
further emphasising the need to clarify the mechanisms that link
LRRK2 and the autophagy-lysosomal pathway.
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